GLP-1 ad war spills into court as Novo Nordisk alleges Eli Lilly ignores science

The competition between major pharmaceutical companies has moved to the courtroom. Novo Nordisk recently filed a lawsuit against Eli Lilly in the U.S. District Court in New Jersey. At the heart of the case is a dispute over how weight-loss drugs are marketed in television advertisements.

Novo Nordisk claims that Eli Lilly uses misleading comparisons in its Zepbound commercials. According to the lawsuit, Eli Lilly specifically highlights data from a head-to-head clinical trial that favors its own product while ignoring newer results for Wegovy. Novo Nordisk points out that the advertisements compare low doses of Wegovy to the highest dose of Zepbound.

By omitting results from the highest dose of Wegovy, which received approval in March, Novo Nordisk alleges that the commercials present an inaccurate picture of performance to the public. They argue that Eli Lilly intentionally selects outdated data to create a false narrative regarding drug efficacy.

Eli Lilly maintains that its advertising complies with regulations. The company states that its commercials include disclosures regarding the nature of the comparison. They describe the clinical trial used as the industry standard for head-to-head testing and suggest that Novo Nordisk is attempting to avoid market competition by seeking legal intervention.